M. Volden

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies.

K. Heider, S. Stilgenbauer, G. Adolf, 2011, Blood.

DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.

H. Döhner, S. Stilgenbauer, A. Kater, 2011, Blood.

, diagnostic implications for functional p 53 testing induced transcriptional program in CLL : biological and − DNA damage

H. Döhner, S. Stilgenbauer, D. T. Raa, 2011 .

DNA damage – induced transcriptional program in CLL : biological and diagnostic implications for functional p 53 testing

H. Döhner, S. Stilgenbauer, D. T. Raa, 2011 .

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

H. Lane, A. Stathis, C. Sessa, 2019, Investigational New Drugs.

In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.

C. Klein, H. Döhner, S. Stilgenbauer, 2009 .